182 related articles for article (PubMed ID: 35019731)
1. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
Oh J; Walker B; Giovannoni G; Jack D; Dangond F; Nolting A; Aldridge J; Lebson LA; Leist TP
Neurodegener Dis Manag; 2022 Feb; 12(1):1-7. PubMed ID: 35019731
[TBL] [Abstract][Full Text] [Related]
2. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
[TBL] [Abstract][Full Text] [Related]
3. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065
[TBL] [Abstract][Full Text] [Related]
4. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
[TBL] [Abstract][Full Text] [Related]
5. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U
Neurodegener Dis Manag; 2023 Feb; 13(1):15-21. PubMed ID: 36545912
[TBL] [Abstract][Full Text] [Related]
6. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
[TBL] [Abstract][Full Text] [Related]
7. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
[TBL] [Abstract][Full Text] [Related]
8. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri D; Pesch VV; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H;
Neurodegener Dis Manag; 2023 Aug; 13(4):215-221. PubMed ID: 37287269
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
[TBL] [Abstract][Full Text] [Related]
10. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A
Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
[TBL] [Abstract][Full Text] [Related]
13. Cladribine Tablets: A Review in Relapsing MS.
Deeks ED
CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
[TBL] [Abstract][Full Text] [Related]
15. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
[TBL] [Abstract][Full Text] [Related]
17. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
De Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist T; Coyle PK; Dangond F; Keller B; Alexandri N; Galazka A
Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
[TBL] [Abstract][Full Text] [Related]
18. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.
Rieckmann P; Centonze D; Giovannoni G; Hua LH; Oreja-Guevara C; Selchen D; Sørensen PS; Vermersch P; Wiendl H; Salloukh H; Yamout B
Neurodegener Dis Manag; 2023 Feb; 13(1):5-13. PubMed ID: 36278394
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
20. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]